Radar · Oncology in England
Best Oncology Companies in England, United Kingdom
The 270 best Oncology companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunocore.
By Riya SenguptaFinancials
270companies tracked
$6.7Bdisclosed funding
0unicorns
170have raised
FLIAR INTELLIGENCE · ONCOLOGY × ENGLAND
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
378kcombined LinkedIn audience
36%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Oncology companies in England
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunocore Developer of bispecific T cell receptor therapies for human diseases | $525M | 47 mo ago | 293 293 → 604 (+106%) · sector median +80% | 2008 | Nicholas Cross Co-Founder | 776 patents Patents concentrated in chemistry & materials | 3 job openings · 1 launch |
| 2 | Apollo Therapeutics Developer of therapeutic programs based on biological and medical research | $372M | 33 mo ago | 11 | 2020 | Richard Mason CEO | — | — |
| 3 | Artios Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer 45Funding top 24%Talent top 28%Moat top 31%Tech top 49% All 8 signals ▾Fundingtop 24% Talenttop 28% Moattop 31% Techtop 49% Markettop 50% Growthbottom 46% Globalbottom 39% Fin. healthbottom 32% Funding: Raised $273M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Talent: 4 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $273M | 7 mo ago | 76 | 2016 | Shweta Nair Founder | — | — |
| 4 | Achilles Therapeutics Developer of T-cell therapies for cancer | $242M | 46 mo ago | 118 | 2016 | Charles Swanton Co-Founder | 56 patents Neoantigen discovery and peptide synthesis for personalized cancer immunotherapy | — |
| 5 | Avacta Developer of drug delivery technology using tumor activated peptide linkers 24Funding top 21%News top 35%Moat top 38%Talent bottom 49% All 11 signals ▾Fundingtop 21% Newstop 35% Moattop 38% Talentbottom 49% Techbottom 47% Patentsbottom 42% Growthbottom 41% Globalbottom 41% Marketbottom 40% Innovationbottom 36% Fin. healthbottom 20% Funding: Raised $222M across 12 rounds · 12 rounds over 15 yrs (0.8/yr) News: 7 BI events in 12 mo (of 34 tracked, 8 types) · -46% YoY rank vs industry peers · Fliar Intelligence Index 24/100 | $222M | 7 mo ago | 90 90 → 47 (-48%) · sector median +80% | 2006 | Christina Coughlin CEO | 17 patents Microfluidic reagent dispensing with optical/Raman detection for nucleic acid analysis | — |
| 6 | Pheon Therapeutics Developer of antibody drug conjugates for treating solid tumor cancers | $188M | 24 mo ago | 8 | 2022 | Bertrand Damour CEO | 37 patents Targeted antibody‑drug conjugates and novel cytotoxic small‑molecule therapeutics. | 1 job opening |
| 7 | Carrick Therapeutics Developer of oncology therapies targeting molecular pathways in resistant cancers | $187M | 42 mo ago | 23 | 2015 | Ash Bahl Co-Founder & Head of Research and Development | 15 patents Small-molecule CDK inhibitors for cancer cell cycle control and apoptosis | — |
| 8 | Autolus Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 28 mo ago | 51 | 2015 | Martin Pule Founder | 648 patents Patents concentrated in chemistry & materials | 1 award |
| 9 | Redx Pharma Developer of small molecule medicines for fibrotic disease and oncology | $163M | 32 mo ago | 89 | 2010 | Lisa Anson CEO | 423 patents Patents concentrated in chemistry & materials | — |
| 10 | Crescendo Biotechnology company developing antibody-based cancer immunotherapies and targeted biologic treatments | $141M | 34 mo ago | 43 | 2009 | Theodora Harold CEO | — | — |
| 11 | Myricx Bio Developer of antibody drug conjugates for the treatment of cancer | $121M | 23 mo ago | 6 | 2019 | Robin Carr CEO | — | — |
| 12 | Healx Provider of AI-powered drug discovery solutions for rare diseases 64Innovation top 25%AI top 26%Moat top 26%Patents top 27% All 12 signals ▾Innovationtop 25% AItop 26% Moattop 26% Patentstop 27% Fundingtop 29% Talenttop 38% Growthtop 42% Techtop 48% Globalbottom 47% Marketbottom 46% Fin. healthbottom 28% Newsbottom 18% Innovation: 105 patents (top 10% of patent-holders) · 57 filings since 2022 vs 48 in 2017-21 AI: Classified as an AI company · Product described with: ai-powered, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $115M | 22 mo ago | 80 80 → 69 (-14%) · sector median +80% | 2014 | David Brown Co-Founder | 105 patents Drug repurposing of existing compounds for rare cancers and polycystic kidney disease | — |
| 13 | Grey Wolf Therapeutics Developer of small molecule based therapeutics for cancer treatment | $113M | 24 mo ago | 7 | 2017 | — | 38 patents Small-molecule modulators of the ERAP1 enzyme for therapeutic drug development. | — |
| 14 | CellCentric Developer of oral small molecule inhibitors for treating blood cancers 50Funding top 21%Talent top 32%News top 33%Growth top 35% All 11 signals ▾Fundingtop 21% Talenttop 32% Newstop 33% Growthtop 35% Patentstop 39% Moattop 43% Partnersbottom 49% Innovationbottom 48% Techbottom 45% Globalbottom 44% Marketbottom 35% Funding: Raised $90.3M across 8 rounds · 8 rounds over 23 yrs (0.3/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $90M | 1 mo ago | 18 | 2003 | Azim Surani Co-Founder | 86 patents Small-molecule epigenetic modulators of p300/CBP acetyltransferase enzymes | 1 launch |
| 15 | Bicycle Developer of synthetic peptide molecules for targeted solid tumor treatment | $90M | 24 mo ago | 40 | 2009 | Greg Winter Co-Founder & Director | 17 patents Design of bicyclic peptide therapeutics and conjugated oligonucleotide drug candidates | — |
| 16 | Enara Bio Developer of T-cell based cancer-cell interface for therapeutics | $84M | 20 mo ago | 38 38 → 68 (+79%) · sector median +80% | 2016 | Kevin Pojasek CEO & President | 63 patents Bispecific polypeptide therapeutics targeting novel cancer antigens for immunotherapy | — |
| 17 | Cytospire Therapeutics Provider of immune cell engagers for treating cancer 53Funding top 24%Global top 45%Talent bottom 49% All 3 signals ▾Fundingtop 24% Globaltop 45% Talentbottom 49% Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 4 countries beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | — | 2023 | Natalie Mount CEO | — | 1 award |
| 18 | Blue Earth Therapeutics Developer of targeted radiopharmaceuticals to treat patients with cancer | $76M | 19 mo ago | — | 2021 | David Gauden Chief Executive Officer | — | 1 award |
| 19 | Charm Therapeutics Developer of menin inhibitors designed for acute myeloid leukemia treatment 50Funding top 24%News top 29%Moat top 31%Growth top 32% All 8 signals ▾Fundingtop 24% Newstop 29% Moattop 31% Growthtop 32% Talenttop 33% Techbottom 49% Globalbottom 37% Marketbottom 29% Funding: Raised $70.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) News: 4 BI events in 12 mo (of 8 tracked, 3 types) · +300% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $70M | 10 mo ago | 16 16 → 32 (+100%) · sector median +80% | 2021 | Laksh Aithani Co-Founder & CEO | — | — |
| 20 | LabGenius Therapeutics Developer of an automated platform for therapeutic antibody discovery | $70M | 24 mo ago | — | 2012 | James Field Founder & CEO | — | 1 job opening · 1 partnership |
| 21 | Accession Therapeutics Developer of therapeutics for cancer treatment | $66M | 25 mo ago | 4 | 2020 | Francis Yuan Co-Founder | — | — |
| 22 | Centauri Therapeutics Developer of immunotherapeutics to treat infectious diseases 35Funding top 26%Growth top 35%Moat top 36%Patents top 46% All 9 signals ▾Fundingtop 26% Growthtop 35% Moattop 36% Patentstop 46% Talentbottom 49% Innovationbottom 42% Globalbottom 42% Techbottom 41% Marketbottom 25% Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $65M | 3 mo ago | 6 | 2014 | Jennifer Schneider CEO | 50 patents Patents concentrated in chemistry & materials | — |
| 23 | Biofidelity Developer of a molecular diagnostic assay for the detection of target DNA sequences | $60M | 26 mo ago | 12 12 → 29 (+142%) · sector median +80% | 2002 | Barney Balmforth Co-Founder & CEO | 70 patents Sensitive nucleic acid and epigenetic marker detection/enrichment technologies | — |
| 24 | T-Therapeutics Developer of T-cell-based rtherapeutics for cancer treatment 62Patents top 12%Innovation top 19%Moat top 26%News top 27% All 10 signals ▾Patentstop 12% Innovationtop 19% Moattop 26% Newstop 27% Fundingtop 30% Growthtop 32% Talenttop 38% Techbottom 47% Globalbottom 45% Marketbottom 32% Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $59M | 7 mo ago | — | 2022 | Haydn Prosser Co-Founder & Director | 239 patents Therapeutic nucleic acid agents for gene expression inhibition (antisense, siRNA, oligonucleotide conjugates). | 1 job opening |
| 25 | Pathios Developer of small molecule based therapeutics for the treatment of cancer | $58M | 15 mo ago | 9 | 2017 | Kirsty McCarthy Co-Founder | — | — |
| 26 | Epsilogen Developer of immunoglobulinE antibodies for the treatment of cancer | $54M | 21 mo ago | 4 | 2016 | Tim Wilson CEO at Epsilogen Ltd | 19 patents Engineered therapeutic antibodies, especially IgE and hybrid formats targeting HER2 low-expression cancers | — |
| 27 | Iksuda Therapeutics Developer of antibody drug conjugates for the treatment of solid cancers | $50M | 14 mo ago | 16 | 2012 | David Simpson Co-Founder & CEO | 29 patents Design and formulation of antibody‑drug conjugates and their linkers for targeted therapy. | — |
| 28 | Mestag Therapeutics Developer of therapeutics for the treatment of cancer and inflammatory diseases 35Talent top 23%Funding top 28%Moat top 39%Tech bottom 46% All 6 signals ▾Talenttop 23% Fundingtop 28% Moattop 39% Techbottom 46% Globalbottom 37% Marketbottom 26% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated Funding: Raised $45.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $45M | 3 mo ago | 8 | 2020 | David Tuveson Co-Founder | — | — |
| 29 | Epitopea Developer of immunotherapeutics for the treatment of cancer | $45M | 19 mo ago | 10 | 2021 | Jon Moore CEO | — | — |
| 30 | NeoPhore Developer of small molecule therapies to treat cancer | $45M | 28 mo ago | 10 10 → 18 (+80%) · sector median +80% | 2017 | Alberto Bardelli Co-Founder | 32 patents Patents concentrated in chemistry & materials | 1 award |
| 31 | Laverock Therapeutics Developer of next generation of programmable cell therapies 24Funding top 29%Moat top 42%Talent bottom 49%Global bottom 45% All 6 signals ▾Fundingtop 29% Moattop 42% Talentbottom 49% Globalbottom 45% Techbottom 43% Marketbottom 27% Funding: Raised $39.3M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $39M | 11 mo ago | 6 | 2021 | David Venables CEO | — | — |
| 32 | Theolytics Developer of oncolytic adenovirus for the treatment of cancer 53Growth top 20%Funding top 29%Patents top 39%Moat top 42% All 10 signals ▾Growthtop 20% Fundingtop 29% Patentstop 39% Moattop 42% Innovationtop 50% Talentbottom 49% Techbottom 47% Globalbottom 42% Marketbottom 35% Newsbottom 18% Growth: Headcount 16 → 26 (+62%) across vintages · Fresh capital in last 24 mo Funding: Raised $33.6M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $34M | 3 mo ago | 26 26 → 30 (+15%) · sector median +80% | 2017 | Charlotte Casebourne Co-Founder & CEO | 14 patents Oncolytic adenovirus vectors for cancer gene therapy and virotherapy | 1 job opening |
| 33 | Leo Cancer Care Manufacturer of upright patient positioning systems for radiation therapy treatments 62Talent top 28%Funding top 31%Growth top 35%Tech top 38% All 7 signals ▾Talenttop 28% Fundingtop 31% Growthtop 35% Techtop 38% Moattop 42% Marketbottom 46% Globalbottom 39% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $25.3M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $25M | 8 mo ago | 55 | 2014 | Paul Keall Co-Founder | — | 1 launch · 1 partnership |
| 34 | Abingdon Health Developer of immunoassays for diagnostic purposes 57Funding top 29%Growth top 33%Market top 46%Moat top 48% All 7 signals ▾Fundingtop 29% Growthtop 33% Markettop 46% Moattop 48% Techbottom 49% Newsbottom 40% Globalbottom 32% Funding: Raised $24.1M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Growth: Headcount 51 → 151 (+196%) across vintages · 2 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $24M | 8 mo ago | 151 151 → 91 (-40%) · sector median +80% | 2008 | — | — | 2 awards |
| 35 | LIfT Biosciences Developer of neutrophil-based cell therapies for solid tumors | $20M | 10 mo ago | 8 | 2016 | — | 69 patents Manufacturing and therapeutic use of engineered immune cells for cancer treatment | — |
| 36 | Valink Therapeutics Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases | $20M | 7 mo ago | — | 2020 | Irsyad Khairil Co-Founder & CTO | — | — |
| 37 | OVM Therapeutic peptide vaccines for cancer | $12M | 19 mo ago | 5 | 2012 | Shisong Jiang Founder & Director | — | — |
| 38 | Lucida Medical Developer of MRI-based cancer screening technology using artificial intelligence (AI) 35Talent top 38%Funding top 44%AI top 45%Moat top 48% All 7 signals ▾Talenttop 38% Fundingtop 44% AItop 45% Moattop 48% Techbottom 48% Globalbottom 37% Marketbottom 27% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $11.5M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $12M | 2 mo ago | 12 12 → 29 (+142%) · sector median +80% | 2019 | Evis Sala Co-Founder | — | — |
| 39 | Tagomics Developer of genomic-based cancer diagnostic platform | $8M | 12 mo ago | 8 | 2020 | — | 13 patents Epigenetic and biomolecular profiling technologies for nucleic acid modification analysis | 1 job opening |
| 40 | Ignota Labs AI-driven toxicity prediction tools for early-stage drug discovery scientists | $7M | 15 mo ago | 9 | 2021 | Layla Hosseini-Gerami Co-Founder | — | 2 partnerships · 1 award |
| 41 | Cyted Leader in non-endoscopic diagnostics for digestive health, enabling early disease detection and access to… 53Talent top 28%Funding top 33%Patents top 33%Growth top 35% All 9 signals ▾Talenttop 28% Fundingtop 33% Patentstop 33% Growthtop 35% Innovationtop 37% Moattop 46% Techbottom 45% Globalbottom 40% Marketbottom 32% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $6.6M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $7M | 9 mo ago | — | 2018 | Maria Odonovan Co-Founder & CMO | 16 patents Minimally invasive esophageal cell‑sampling devices for Barrett's cancer detection | — |
| 42 | NK:IO Developer of small molecule therapies for hematological and solid tumors | $7M | 18 mo ago | 1 | 2020 | Matthew Fuchter Co-Founder | — | — |
| 43 | Scancell Biotechnology company developing immunotherapies for cancer treatment | $6M | 18 mo ago | 22 | 1996 | Phil Huillier CEO | 167 patents Glycoengineered therapeutic antibodies and vaccine antigens targeting fucosylated cancer markers | 1 award |
| 44 | AMLo Biosciences Developer of a prognostic test for the early detection of cancer | $6M | 18 mo ago | 11 | 2017 | Penny Lovat Co-Founder | 32 patents Cancer diagnostic biomarkers and therapeutic antibodies for melanoma and squamous cell carcinoma | — |
| 45 | Oxford Cancer Analytics Provider of a platform for detection of lung cancer | $5M | 17 mo ago | 7 | 2018 | Andreas Halner Co-Founder | — | — |
| 46 | Athernal Bio Developer of vaccines to target and lower the risk of cancer and other age-related diseases | $5M | 8 mo ago | — | 2024 | Nirupa Desai Co-Founder | — | — |
| 47 | Oxilio Developer of therapeutics for cancer treatment | $5M | 21 mo ago | 1 | 2020 | Ralph Browning Co-Founder | — | — |
| 48 | QV Bioelectronics Manufacturer of electrotherapy devices for treating brain tumors | $4M | 4 mo ago | 6 | 2019 | Christopher Bullock Co-Founder & CTO | 25 patents Implantable bioelectronic devices for neural stimulation and monitoring | — |
| 49 | Semarion Provider of a platform for drug discovery and screening | $3M | 2 mo ago | 3 | 2018 | Jeroen Verheyen Co-Founder & CEO | 4 patents Patents concentrated in computing, sensing & instrumentation | — |
| 50 | Combat Medical Manufacturer of medical device for curing bladder cancer | $683K | 4 mo ago | 13 13 → 25 (+92%) · sector median +80% | 2008 | Alberto Albalat Founder | — | — |
Top 12 Oncology companies in England
#1
Series D · Cambridge, England · founded 2003 · 18 employees$90.3Mraised▾
Series D · Cambridge, England · founded 2003 · 18 employees
Developer of oral small molecule inhibitors for treating blood cancers. This pharmaceutical entity focuses on creating therapeutic agents that target specific proteins involved in tumor progression. The research involves modulating gene expression by disrupting the interaction of transcription co-activation factors within cancer cells. The primary therapeutic candidate is designed to address multiple myeloma and other hematological malignancies by binding to bromodomains. This approach aims to reduce the production of proteins that drive tumor growth. The development process includes clinical evaluation to assess safety and efficacy across various patient populations.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 21%Talent
top 32%News
top 33%Growth
top 35%Patents
top 39%Moat
top 43%Funding: Raised $90.3M across 8 rounds · 8 rounds over 23 yrs (0.3/yr) · Last round Series D (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated · 4 leadership moves in 12 mo
News: 6 BI events in 12 mo (of 18 tracked, 6 types) · +50% YoY · 1 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 7k LinkedIn followers
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series D$220M
- May 2025Series C$120M
- Jul 2024Series C$35M
- Jul 2023Series C$25M
Founders & team
Investors
Takeda Ventures, Morningside, Nesta Impact Investments, Providence Investment Company, UK Innovation Science & Seed Fund, RA Capital Management
Tech stack
CloudflareCloudflare Browser InsightsCookieyesCore-JsDocusignElementor
#2
Series A · London, England · founded 2023$83Mraised▾
Series A · London, England · founded 2023
Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 24%Global
top 45%Talent
bottom 49%Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (May 2026)
Global: Investors from 4 countries beyond United Kingdom
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- May 2026Series A$83M
- Seed—
Founders & team
Investors
4Bio Capital, Servier, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth
#3
Series D · Cambridge, England · founded 2016 · 76 employees$273Mraised▾
Series D · Cambridge, England · founded 2016 · 76 employees
Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer. These treatments focus on inhibiting specific enzymes involved in cellular repair mechanisms to induce damage within malignant tissues. The approach utilizes small-molecule inhibitors to disrupt survival pathways in tumor cells. Research efforts concentrate on identifying biological targets that regulate replication stress and genomic stability. These therapeutic candidates are evaluated for use as monotherapies or in combination with other agents to address solid tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 24%Talent
top 28%Moat
top 31%Tech
top 49%Market
top 50%Growth
bottom 46%Funding: Raised $273M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series D (Nov 2025)
Talent: 4 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series D$115M
- Jul 2021Series C$153M
- Aug 2018Series B$84M
- Sep 2016Series A$36M
Founders & team
Investors
Andera Partners, Life Sciences Partners, Novartis, Arix Bioscience, SV Health Investors, IP Group
Tech stack
BootstrapCloudflareCloudflare Bot ManagementCookie InformationFont AwesomeGodaddy
#4
Series A · Kent, England · founded 2014 · 6 employees$64.9Mraised▾
Series A · Kent, England · founded 2014 · 6 employees
Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Growth
top 35%Moat
top 36%Patents
top 46%Talent
bottom 49%Innovation
bottom 42%Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) · Last round Series A (Feb 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 50 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Feb 2026Series A$8.1M
- Jul 2025Grant (prize money)$5.1M
- Nov 2024Grant (prize money)$1.3M
- Jul 2023Series A$11.5M
Founders & team
Investors
Kent County Council, EJ Capital, Wren Capital, Discovery Park, Renaissance Capital Partners, Animatrix Capital Llp
Tech stack
CookiebotGodaddyGoogle AnalyticsHstsJqueryMicrosoft 365
#5
Public · London, England · founded 2006 · 90 employees$222.2Mraised▾
Public · London, England · founded 2006 · 90 employees
Developer of drug delivery technology using tumor activated peptide linkers. This technology attaches peptides to existing therapeutic agents to maintain them in an inactive state while circulating in the bloodstream. The drug remains inactive until it reaches the tumor site, where specific enzymes remove the peptide to release the active medication. This mechanism concentrates the therapeutic effect within the tumor environment.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 21%News
top 35%Moat
top 38%Talent
bottom 49%Tech
bottom 47%Patents
bottom 42%Funding: Raised $222M across 12 rounds · 12 rounds over 15 yrs (0.8/yr) · Last round Post IPO (Oct 2025)
News: 7 BI events in 12 mo (of 34 tracked, 8 types) · -46% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 17 patents
Audience (LinkedIn): 9k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$21.5M
- Aug 2025Post IPO$4.4M
- Feb 2024Post IPO$32.5M
- Nov 2022Post IPO$73.1M
Founders & team
Investors
Mrc, IP Group, Swarraton Partners, WG Partners
Tech stack
AddtoanyAddtoany Share ButtonsAosApple Icloud MailCdnjsCloudflare
#6
Series A · Cambridge, England · founded 2020 · 8 employees$45Mraised▾
Series A · Cambridge, England · founded 2020 · 8 employees
Developer of therapeutics for the treatment of cancer and inflammatory diseases. The company has developed therapeutics that interrupt pathological fibroblast-driven immune signaling and influence innate and adaptive immune responses.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 23%Funding
top 28%Moat
top 39%Tech
bottom 46%Global
bottom 37%Market
bottom 26%Talent: 6 named leaders on record · 6 C-suite/founder profiles curated
Funding: Raised $45.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Mar 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers — 2.1% of this cohort's audience
Funding rounds
- Mar 2026Series A$40M
- Aug 2024Grant (prize money)$2M
- Aug 2021Seed$34M
- Apr 2021Seed$11M
Founders & team
Investors
Forbion, Google Ventures, SV Health Investors, Johnson & Johnson Innovation, Northpond Ventures, Ukri
#7
Series B · Headington, England · founded 2017 · 26 employees$33.6Mraised▾
Series B · Headington, England · founded 2017 · 26 employees
Developer of oncolytic adenovirus for the treatment of cancer. The company uses a phenotypic screening platform with viruses, particularly adenoviruses, to develop targeted candidates suitable for intravenous delivery and optimized for specific patient populations.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Growth
top 20%Funding
top 29%Patents
top 39%Moat
top 42%Innovation
top 50%Talent
bottom 49%Growth: Headcount 16 → 26 (+62%) across vintages · Fresh capital in last 24 mo
Funding: Raised $33.6M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Grant (prize money) (Mar 2026)
Patents: 14 patents matched (strict assignee match) · 12 filings since 2022 vs 2 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Associate Scientist, Project Manager
Funding rounds
- Mar 2026Grant (prize money)$9.3M
- Sep 2024Grant (prize money)$2.6M
- Apr 2024Series B$23.6M
- Jul 2021Series A—
Founders & team
Investors
Sound Bioventures, M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Oxford University Innovation
#8
Series A · Cambridge, England · founded 2022$59.4Mraised▾
Series A · Cambridge, England · founded 2022
Developer of T-cell-based rtherapeutics for cancer treatment. It offers T-cell receptor-based drugs that recognise specific cancers and patient’s own T cells to kill the cancer cells and eradicate the tumour.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 12%Innovation
top 19%Moat
top 26%News
top 27%Funding
top 30%Growth
top 32%Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 · Latest publication 2026
Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21
Moat: Editorial + unicorn rating 8/10 · IP moat: 239 patents · Soonicorn
Audience (LinkedIn): 7k LinkedIn followers
Hiring (LinkedIn): 4 hiring posts in 12 mo (public) · momentum -2 · hiring: Senior Scientist - Analytical Development, Protein Sciences, Research Associate - Protein Sciences
Funding rounds
- Nov 2025Series A$32M
- Nov 2023Series A$59.4M
Founders & team
Investors
Sanofi Ventures, University of Cambridge, Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital
Tech stack
Animate.CssAnime.JsExactmetricsFancyboxGodaddyGoogle Analytics
#9
Series A · Cambridge, England · founded 2019 · 12 employees$11.5Mraised▾
Series A · Cambridge, England · founded 2019 · 12 employees
Lucida Medical develops MRI-based cancer screening technology using artificial intelligence (AI). The old name of the company was Cambridge AI Health. The company aims to develop novel algorithms for biomedical discovery, omics analytics, early diagnostics, and clinical trials.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 38%Funding
top 44%AI
top 45%Moat
top 48%Tech
bottom 48%Global
bottom 37%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $11.5M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) · Last round Series A (Mar 2026)
AI: Product described with: artificial intelligence
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Mar 2026Series A$11.5M
- Mar 2021Seed—
Founders & team
Investors
XTX Markets, IW Capital, Macmillan Cancer Support, Sahsen Ventures, University of Cambridge, The FSE Group
Tech stack
CloudflareCloudflare Bot ManagementContact Form 7DiviExactmetricsGoogle Analytics
#10
Series B · London, England · founded 2021 · 16 employees$70Mraised▾
Series B · London, England · founded 2021 · 16 employees
Developer of menin inhibitors designed for acute myeloid leukemia treatment. The focus is on designing structurally optimised inhibitors that bind within the KMT2A interface. The aim is to overcome treatment resistance in acute myeloid leukemia.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 24%News
top 29%Moat
top 31%Growth
top 32%Talent
top 33%Tech
bottom 49%Funding: Raised $70.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series B (Aug 2025)
News: 4 BI events in 12 mo (of 8 tracked, 3 types) · +300% YoY · Top themes: Funding, Capital raise
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 13k LinkedIn followers — 3.5% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Aug 2025Series B$80M
- Apr 2023Series A$20M
- Jun 2022Series A$50M
Founders & team
Investors
F-Prime Capital, Orbimed, General Catalyst, Khosla Ventures, Axial Adventure, Braavos
Tech stack
Animate.CssAnime.JsExactmetricsFancyboxGoogle AnalyticsGoogle Font Api
#11
Public · York, England · founded 2008 · 151 employees$24.1Mraised▾
Public · York, England · founded 2008 · 151 employees
Developer of immunoassays for diagnostic purposes. It offers a rapid lateral flow immunoassay system that enables multiplexed immunodiagnostics. Its flagship product Seralite- FLC measures kappa (K) and lambda (λ) immunoglobulin-free light chain used for the detection of hematological cancers. It als provide research services for a range of sectors including the clinical point of care, clinical self-test, pharmaceutical, and others.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 29%Growth
top 33%Market
top 46%Moat
top 48%Tech
bottom 49%News
bottom 40%Funding: Raised $24.1M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) · Last round Post IPO (Oct 2025)
Growth: Headcount 51 → 151 (+196%) across vintages · 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Market: 151 employees (top 12% of Life Sciences) · Top-10,000,000 web property
Audience (LinkedIn): 7k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Oct 2025Post IPO$4.4M
- Jan 2019Series A$2.6M
- Dec 2017Series A$1.5M
- Jul 2016Series A$3.9M
Investors
Imperial Innovations, Mercia, IP Group, Northern Powerhouse Investment Fund
Tech stack
Apple Icloud MailCloudflareCloudflare Browser InsightsCookieyesGoogle AnalyticsGoogle Font Api
#12
Series D · Crawley, England · founded 2014 · 55 employees$25.3Mraised▾
Series D · Crawley, England · founded 2014 · 55 employees
Manufacturer of upright patient positioning systems for radiation therapy treatments. These systems enable the delivery of radiation while patients remain in a seated or standing position. The equipment integrates with imaging technology to support simulation and treatment workflows. By utilizing upright positioning, the hardware facilitates compatibility with various radiation beam delivery systems. The design focuses on patient stability and comfort during the administration of therapeutic radiation.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Talent
top 28%Funding
top 31%Growth
top 35%Tech
top 38%Moat
top 42%Market
bottom 46%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $25.3M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (Sep 2025)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 14k LinkedIn followers — 3.6% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. RaySearch) announced in 12 mo
Funding rounds
- Sep 2025Series D$40M
- Jun 2024Series C—
- Jul 2021Series B$25.3M
Founders & team
Investors
Pureland Group, Yu Galaxy, Alumni Ventures, Serra Ventures, Cosylab, Toret Devices
Tech stack
BootstrapCookieyesCore-JsGodaddyGoogle AnalyticsGsap
Funding & investor landscape
$6.7Btotal disclosed funding
159companies funded
580disclosed rounds
4rounds last 90 days
Most active investors
Gov19 rounds
Notable founders
Azim Surani
Co-Founder · CellCentric
Will West
Co-Founder & CEO · CellCentric
Natalie Mount
CEO · Cytospire Therapeutics
Shweta Nair
Founder · Artios
Elena Seroff
Artist. Art Director. Curator. Founder · Artios
Jennifer Schneider
CEO · Centauri Therapeutics
Christina Coughlin
CEO · Avacta
David Tuveson
Co-Founder · Mestag Therapeutics
Soumya Raychaudhuri
Co-Founder · Mestag Therapeutics
Charlotte Casebourne
Co-Founder & CEO · Theolytics
Haydn Prosser
Co-Founder & Director · T-Therapeutics
Allan Bradley
Co-Founder & CEO · T-Therapeutics
Prism market signals · United Kingdom · country-scoped Prism corpus, 1,711,828 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United Kingdom
How research on Oncology & Cancer Therapeutics is moving in the United Kingdom
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,900 United Kingdom-affiliated papers.
research sentiment over time
200920182026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 23% → 64% across 2009–2026.
top research entities
- University College London121
- Ludwig Cancer Research115
- Cancer Research UK108
- Imperial College London99
- King's College London96
leading researchers
James Monkman · Eyad Elkord · Ping‐Chih Ho · John Maher · David J. Pinato · Eleni Maniati · Dmytro Klymyshyn · Dochniak, Michael John
▲
Breakthroughs632 · 33%
▲ 29%→34% share
▲1.2× share momentum1 median citations89% since 2021mostly methods-led
Tumor microenvironment breakthrough research is surging — UK papers rose from 19 to 256, driving field-share to 34%.
rising sub-themes (early→recent)
- Tumor microenvironment19→256
- Immune system11→177
- Immunotherapy5→165
- Cancer research28→177
- Cancer immunotherapy4→91
Newly emergingTranscriptome 0→27 · Prostate cancer 0→19 · Cell 0→18
Landmark Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer · 2,400 cites
◆
Advancements826 · 43%
▲ 40%→44% share
▲1.1× share momentum2 median citations90% since 2021mostly empirical
Breast cancer advancement research newly emerged with 59 papers as immunotherapy advancements scaled from 13 to 266.
rising sub-themes (early→recent)
- Tumor microenvironment26→365
- Immune system12→308
- Immunotherapy13→266
- Cancer research36→245
- Cancer immunotherapy7→107
Newly emergingBreast cancer 0→59 · Transcriptome 0→41 · Pancreatic cancer 0→37
Landmark Reprogramming of fatty acid metabolism in cancer · 1,574 cites
▼
Concerns251 · 13%
▼ 16%→13% share
▼0.8× share momentum5 median citations84% since 2021mostly reviews
Immunotherapy safety concerns are intensifying — UK concern-flagged papers grew tenfold from 10 to 101, with immune-checkpoint risks newly emerging.
rising sub-themes (early→recent)
- Immunotherapy10→101
- Tumor microenvironment11→85
- Immune system10→75
- Cancer research5→46
- Cancer immunotherapy5→44
Newly emergingImmune checkpoint 0→18 · Clinical trial 0→14 · Disease 0→14
Landmark A framework for advancing our understanding of cancer-associated fibroblasts · 3,630 cites
RESEARCH HOTSPOTS · United Kingdom
Where oncology is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
London447 · +0.52
Oxford115 · +0.51
Bristol79 · +0.55
Manchester74 · +0.44
Cambridge62 · +0.59
Edinburgh61 · +0.52
Glasgow50 · +0.54
Birmingham34 · +0.52
PATENT SIGNAL · United Kingdom
Who's filing oncology patents in the United Kingdom
United Kingdom oncology patent filing is accelerating — 132 filings from 53 assignees (2016–2025), led by Immodulon Therapeutics, Tufts College, Avacta LIFE Sciences; annual filings 6→20.
132 filings53 assigneespeak 22/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Immodulon Therapeutics45
- Tufts College16
- Avacta LIFE Sciences16
- Oxford Biotherapeutics8
- Daiichi Sankyo7
- Astrazeneca UK7
- Cambridge Entpr7
- UNIV Virginia Patent Foundation6
Common questions
How many Oncology companies are there in England, United Kingdom?
Radar tracks 270 indexable Oncology companies headquartered in England, United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in England, United Kingdom?
The Oncology companies in England, United Kingdom on this list have raised a combined $6.7B in disclosed equity funding across 159 funded companies.
Which is the highest-funded Oncology company in England, United Kingdom?
Immunocore is the highest-funded Oncology company in England, United Kingdom, with $525M in disclosed equity funding.
How many Oncology companies in England, United Kingdom are funded?
159 of the 270 Oncology companies in England, United Kingdom on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in England, United Kingdom?
None of the Oncology companies in England, United Kingdom on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in England, United Kingdom Oncology companies?
The most active investors in England, United Kingdom Oncology companies on this list include Gov, Ukri, Europa, Oxford University Innovation, University of Cambridge.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.